.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical consequence of 11 months, people along with metastatic stomach growths who got biomarker-matched therapies based upon circulating growth DNA profiling revealed a better medical advantage than those acquiring unequaled treatment.